LAFAYETTE, Ind.

A precious moment with a loved one suffering from Alzheimer's disease can mean the world, and a groundbreaking treatment now available at IU Health Arnett aims to extend that time.

The innovative drug, Lecanemab, has made headlines as the first fully FDA-approved treatment specifically targeting Alzheimer's in the United States. Dr. Hongkui Jing, a neurologist at IU Health Arnett, describes the drug as revolutionary, emphasizing its unique approach: it treats the underlying disease rather than just alleviating symptoms.

"While there is currently no cure for Alzheimer's, which is crucial to comprehend, this treatment can empower patients to maintain their independence and cognitive functions for a longer duration," said Dr. Jing. "It allows individuals to engage more fully in daily life and maximizes quality time for families before symptoms advance."

Lecanemab requires patients to undergo thorough evaluations to confirm that they are in the appropriate stage for treatment. Dr. Jing noted that the ideal candidates typically present with mild to early moderate dementia, making them eligible for this promising therapy.

Since its market introduction in 2023, extensive training is mandated for physicians aiming to administer Lecanemab, with Dr. Jing currently being the sole qualified provider at IU Health Arnett. The financial aspect is also reassuring; Medicare generally covers about 80% of the costs associated with the biweekly intravenous infusions, while private insurance often picks up the remaining balance.

While Lecanemab does not provide a permanent solution for Alzheimer's—the disease will inevitably progress—its introduction signifies a significant step forward in extending the precious time patients and families have together. "Dementia doesn't just affect one individual; it impacts entire families," Dr. Jing noted, illustrating the broader implications of this treatment.

Additionally, Stephanie Veach, a registered nurse at IU Health Arnett, highlighted another key benefit: Lecanemab can now be administered right in Lafayette, eliminating the need for patients to travel to Indianapolis for treatment. "This is a huge convenience for our patients, especially older adults who may struggle with long journeys," Veach explained.

The early experiences with Lecanemab show promising results; patients express gratitude for the accessibility of this option. Veach recounted a poignant story about a patient motivated by family history to seek treatment: "He is pursuing this for his children and nieces and nephews, ensuring they know there are options and hope if faced with a similar diagnosis in the future."

As IU Health Arnett moves forward with this treatment, they emphasize the importance of establishing trust with their patients, being the primary care providers for many in the community. The infusion centers at IU Health White Memorial and IU Health Arnett Frankfort are also set to begin administering Lecanemab shortly, further enhancing access to this vital care.

In summary, having the opportunity to receive Lecanemab close to home is a monumental shift for patients and their families. "Receiving care in a familiar environment fosters comfort, allowing us to forge stronger connections while maintaining high standards of medical care," Veach said, echoing the sentiments of many who benefit from this remarkable advancement.

Stay tuned for more updates on how this transformative treatment is changing lives in Lafayette and beyond!